SG3 Management’s Immunic IMUX Stock Holding History

SG3 Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,710	Closed	-$129K	–	370
2022 Q2	$129K	Buy	3,710 +1,710	+86%	+$110K	0.02%	304
2022 Q1	$226K	Buy	+2,000	New	+$232K	0.01%	742

Other funds holding IMUX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SG3 Management's IMUX Position: Q2 2022 in Review

SG3 Management sold out of Immunic (IMUX) in Q2 2022, closing a stake of 2,090 shares — an estimated $134K sold.

SG3 Management first reported a position in IMUX in Q1 2022 and held it in 1 quarter. The position peaked at $236K in Q1 2022. 72 funds tracked by Wall St. Rank hold IMUX as of Q2 2022.

SG3 Management reported no remaining Immunic position as of Q2 2022 after selling out during the quarter.
SG3 Management sold 2,090 Immunic shares in Q2 2022, an estimated $134K.
SG3 Management first reported a position in Immunic in Q1 2022 and held it in 1 quarter.
SG3 Management's Immunic position peaked at $236K in Q1 2022.
72 funds tracked by Wall St. Rank held Immunic as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.